Stay updated on PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.

Latest updates to the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page
- Check3 days agoChange DetectedA minor revision update from v3.3.3 to v3.3.4 is shown, with no substantive changes to the page content.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedAdded location listings for multiple regions (Arkansas, California, Michigan, Missouri, Ontario, Hong Kong, FC, MI, PN, Catalonia) and updated the revision to v3.3.3; removed the HHS Vulnerability Disclosure link and related location sections.SummaryDifference0.9%

- Check46 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2. No substantive study details or user-facing content appear to be changed.SummaryDifference0.0%

- Check54 days agoChange DetectedPublications note updated to indicate items are automatically filled from PubMed and may not relate to the study; page revision updated to v3.3.1.SummaryDifference0.1%

- Check61 days agoChange DetectedA government funding status notice was removed from the page. The study details themselves appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check75 days agoChange DetectedTwo screenshots show only minor UI/formatting differences with no changes to study details, eligibility criteria, or interventions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.